All In Biotech

Drug Trial Radar · NCT05505955

Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency

A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of Single and Multiple Dose of HRS-5965 Tablets in Healthy Subjects, and the Food Effect on Pharmacokinetics, and Pharmacokinetics in Subjects With Impaired Renal Function

Last checked: Nov 20, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

83

Actual

Start

Oct 8, 2022

Primary completion

Nov 3, 2023

Study completion Nov 3, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The trial is the first human trial. The safety, tolerability, PK and PD of HRS-5965 tablets will be evaluated in healthy subjects and subjects with impaired renal function. The study was divided into three parts: Part 1: single ascending dose, randomized, double-blind study,with 6 dose groups preset, of which 1 group will be administered under fasted and fed conditions; Part 2: Multiple ascending dose, randomized, double-blind study,with 4 dose groups preset; Part 3: an open-label, nonrandomized, single-dose study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS -5965 compared to demographically-matched healthy participants with normal renal function.

Conditions

  • Glomerulonephritis

Interventions

  • HRS-5965Drug

    Subjects took HRS5965 tablets in Part 1, Part 2 and Part 3.

  • PlaceboDrug

    Subjects took Placebo in Part 1 and Part 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and severity of adverse events to assess safety and tolerabilityTime frame: up to 24 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Affiliated hospital of QingDao University

    Qingdao, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.